Medibio Signs Clinical Trial Agreement with US-based MedBridge Healthcare LLC For the Depressive Burden Trial

Melbourne, Australia & Minneapolis, MN

Medibio Limited (“MEB” or the “Medibio”)(ASX: MEB)(OTCPINK: MDBIF), a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of certain mental health conditions, is pleased to announce that it has entered into a Clinical Trial Agreement (“CTA”) with MedBridge Healthcare LLC (“MedBridge”), to support Medibio’s Sleep Analysis of Depressive Burden (“SADB”) trial. The SADB trial aims to identify clinical depressive burden in patients with sleep disturbance who undergo a sleep study in a clinical environment.

MedBridge is the leading national provider of sleep laboratory management services and operates over 130 sleep disorder diagnostic centers across the US, performing over 70,000 sleep disorder diagnostic procedures annually. MedBridge partners with hospitals and physician practices to offer comprehensive, fully-integrated services for the identification, testing, diagnosis, therapeutic coordination, and long-term care management of patients with sleep disorders.

Under the CTA, MedBridge in collaboration with Ohio Sleep Solutions in Columbus, Ohio will coordinate research guidelines and services for the purposes of the SADB trial to help fast-track patient recruitment.

John Mathias, Chief Development Officer of MedBridge said “As the leading sleep management service provider in the US, we are excited about the potential of Medibio’s technology and its clinical applications. The objective identification of depression in patients that suffer certain sleep disorders is an unmet need and we are pleased to be working with Medibio to fast-track patient recruitment for the SADB trial.”

Claude Solitario, Managing Director of Medibio Ltd said, “We are delighted to have MedBridge as a partner for our sleep analysis of depressive burden trial. Their expertise and reputation in sleep medicine in the United States is exemplary. In addition, the size of MedBridge’s operations will ensure that our SADB trial will be undertaken quickly and efficiently. MedBridge’s willingness to participate in the collaboration is a testament to the quality of our research team and merit of our endeavor.”

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.